NCT02451982Active, not recruitingPhase 2
Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
A Platform Study of Combination Immunotherapy for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
This platform trial will evaluate various immunotherapy combinations given in the neo-adjuvant and adjuvant setting in patients with surgically resectable pancreatic ductal adenocarcinoma.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 76 (estimated)
- First submitted
- 20 May 2015
- Start date
- 28 Mar 2016
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Diseases
- Pancreatic cancer
- NCT number
- NCT02451982
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 76
- From 28 Mar 2016 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received any type of anti-cancer treatment or immunotherapy for pancreas cancer
- Systemically steroid use within 14 days
Other illness
- History of autoimmune disease (Graves or Hashimoto's disease, vitiligo, and type I diabetes are allowed)
- Evidence of active infection
- Diagnosed with another cancer or myeloproliferative disorder (some exceptions)
- History of severe hypersensitivity reaction to any monoclonal antibody or known component of the study drugs
- Known history of infection with HIV, hepatitis B, or hepatitis C
Other
- Pregnant or lactating
- Oxygen saturation of \<92% on room air by pulse oximetry
- On home oxygen
Who the study is looking for
- Newly diagnosed or clinically-suspected adenocarcinoma of the head, neck, or uncinate process of the pancreas
- Tumor must be surgically resectable
- ECOG Performance Status of 0 to 1
- Adequate organ function as defined by study-specified laboratory tests
- Must agree to use acceptable form of birth control
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Coordinator of this site? Confirm its status | Baltimore | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.